Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Partially self-financed daily Truvada PrEP study in high-risk MSM
ChiCTR-OPC-16009603Phase 4Recruiting
- Sponsor
- Stanley Ho Centre for Emerging Infectious Diseases
- Start
- Jan 1990
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV), sponsored by Stanley Ho Centre for Emerging Infectious Diseases. Primary endpoints: Acceptability of PrEP and Proportion fully adherent to daily PrEP. Started Jan 1990; status: recruiting.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR-OPC-16009603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-16009603.